Table 2.
Demographic Data for Adult (≥18 y) Norwegian Kidney Transplant Recipients Alive by April 20, 2020, Divided by if They Responded (Kidney Transplant Responders) to the Life Situation Form or Not (Remaining Kidney Transplant Recipients)
| Kidney Transplant Responders (n = 1,007) | Remaining Kidney Transplant Recipients (n = 2,589) | P Value | |
|---|---|---|---|
| Age (y) | 56.6 ± 12.6 | 59.0 ± 15.1 | <0.001 |
| Missing data | 0 | 0 | |
| BMI (kg/m2) | 26.6 ± 5.6 | 26.6 ± 6.5 | >0.99 |
| Missing data | 44 | 124 | |
| Time since transplant (y) | 10.2 ± 8.4 | 10.5 ± 8.4 | 0.41 |
| Median (25% percentile, 75% percentile) | 8.3 (3.6, 14.6) | 8.7 (4.0, 14.6) | |
| Missing data | 0 | 0 | |
| Preemptive transplant | 324 (32.2%) | 638 (24.6%) | <0.001 |
| Missing data | 0 | 0 | |
| First transplant | 838 (83.2%) | 2,246 (86.8%) | 0.006 |
| Missing data | 0 | 0 | |
| Combined transplantationa | 51 (5.1%) | 152 (5.9%) | 0.35 |
| Missing data | 0 | 0 | |
| Living donor | 434 (43.1%) | 452 (17.5%) | <0.001 |
| Missing data | 0 | 0 | |
| Plasma creatinine (μmol/L) | 130 ± 63 | 133 ± 68 | 0.23 |
| Missing data | 42 | 120 | |
| Immunosuppression | |||
| Missing data | 0 | 0 | |
| Tacrolimus | 635 (63.1%) | 1,608 (62.1%) | 0.27 |
| Cyclosporine | 252 (25.0%) | 695 (26.8%) | 0.60 |
| Mycophenolate | 820 (81.4%) | 2,208 (85.3%) | 0.01 |
| Prednisolone | 941 (93.4%) | 2,409 (93.0%) | 0.67 |
| mTOR inhibitor | 66 (6.6%) | 169 (6.5%) | 0.98 |
| SARS-CoV-2 | |||
| Measured SARS-CoV-2 IgG | 815 (80.9%) | 1,303 (50.3%) | <0.001 |
| SARS-CoV-2 IgG positive | 0 (0.0%) | 8 (0.3%) | 0.27b |
| COVID-19 | 0 (0.0%) | 20 (0.8%) | 0.005 |
| Hypertension, BP ≥140/90 mmHg | 423 (43.5%) | 887 (35.5%) | 0.84 |
| Missing data | 36 | 90 | |
| Taking antihypertensive medication | 804 (80.0%) | 1,665 (64.6%) | 0.19 |
| Missing data | 2 | 12 | |
| BP ≥140/90 mmHg and/or antihypertensive drugs | 864 (88.8%) | 1,785 (71.3%) | 0.26 |
| Missing data | 34 | 85 | |
| Age over 65 y | 274 (27.2%) | 1,038 (40.1%) | <0.001 |
| Missing data | 0 | 0 |
Note: Data are presented as mean (± standard deviation) or numbers (%). Data analyzed with R and with independent samples t test or χ2 test. Abbreviations: BMI, body mass index, BP, blood pressure; COVID-19, coronavirus disease 2019; mTOR; mammalian target of rapamycin; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a
Combined with pancreas, liver, or heart.
b
Number of positive samples in relation to those taking a sample.